Navigation Links
Takeda Submits New Drug Application in the U.S. for Investigational Type 2 Diabetes Therapy, Fixed-Dose Combination Alogliptin/Metformin
Date:11/23/2011

OSAKA, Japan and DEERFIELD, Ill., Nov. 23, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) announced today that its wholly-owned subsidiary Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for the fixed-dose combination therapy alogliptin/metformin, which combines alogliptin with metformin in a single tablet. The FDA is expected to review the NDA submission within the next ten months, the standard review period for a new application.

"This NDA submission further extends Takeda's commitment to offering patients with type 2 diabetes a range of therapeutic options to help them manage their condition," noted Thomas Strack, M.D., vice president, clinical science, Takeda Global Research & Development Center, Inc., U.S. "The worldwide incidence of type 2 diabetes continues to expand at a rapid rate and we continue our research into additional medications to treat these patients."

Alogliptin is a selective dipeptidyl peptidase IV inhibitor (DPP-4i) under investigation in the U.S. for the treatment of type 2 diabetes as an adjunct to diet and exercise. Discovered by Takeda San Diego, Inc., alogliptin is designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide), which play roles in regulating blood glucose levels. Metformin is a widely used diabetes medication that acts primarily by reducing the amount of glucose produced by the liver. These medications work in combination to help patients with type 2 diabetes manage their blood glucose levels.  

Common adverse reactions reported in greater than or equal to 5 percent of patients treated with co-administration of alogliptin with metformin were: upper respiratory tract infection, nasopharyngitis, creatinine renal clearance decreased, diarrhea, headache, hypertension, and urina
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. U.S. Food and Drug Administration (FDA) Delays Review of Takedas Investigational Type 2 Diabetes Therapies, Alogliptin and Alogliptin/Pioglitazone
2. Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
3. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
4. Takeda Completes Acquisition and Names New CEO of Nycomed
5. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
6. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
7. Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
8. Takeda to Acquire Nycomed
9. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
10. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
11. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... LAKEWOOD, Colo. , Dec. 15, 2014  The Government of ... the collaboration of AABB, Global Blood Fund (GBF) and Terumo BCT ... Africa , as well as provide long-term health system capacity ... Key Facts: , The Ghanaian Ebola Readiness and Resilience ... Ghana,s preparations for the possible arrival of ...
(Date:12/13/2014)... , Dec. 11, 2014 Research and ... the addition of the "Drug Injection Devices ... http://photos.prnewswire.com/prnh/20130307/600769 ... of an expanding list of health conditions, drug ... that simplify the administration process and increase the ...
(Date:12/13/2014)... HUNTSVILLE, Ala. , Dec. 12, 2014 /PRNewswire-USNewswire/ ... has purchased the HiSeq X Ten sequencing system ... will enable HudsonAlpha to produce and analyze genomic ... purchase stems from the Institute,s commitment to research ... The HiSeq X Ten provides unprecedented capacity, ...
Breaking Medicine Technology:Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 2Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 3Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 4Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 5Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 6Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
... The " Global Endoscopy Market by Product, ... and studies the major market drivers, restraints, and opportunities in Americas, ... Browse market data tables and in-depth TOC of   ... & Technology (2011- 2016) " ...
... 2012 Oncos Therapeutics today announced the successful ... oncolytic adenovirus suggested as a potential new treatment for many ... the safety assessment part of the study. " ... r thern Europe to start a clinical study ...
Cached Medicine Technology:MarketsandMarkets: Global Endoscopy Market worth $9.7 Billion by 2016 2MarketsandMarkets: Global Endoscopy Market worth $9.7 Billion by 2016 3Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers 2
(Date:12/17/2014)... No matter how far modern medicine advances, ... head louse parasite—a common childhood malady and a source ... six and twelve million individuals will suffer an infestation. ... company comes to the rescue, providing an all-natural treatment ... track record of customer service, and effectiveness in getting ...
(Date:12/17/2014)... Alan Mozes HealthDay ... In the world of infectious diseases, one worrisome phenomenon is ... people. The process -- known as zoonosis -- is ... look for signs that an animal-borne disease might make inroads ... just such a development -- and the culprits in this ...
(Date:12/17/2014)... Alan Mozes HealthDay Reporter ... party season fast approaching, a new study reveals that states ... have fewer drunk drivers on their roads. The finding ... are better able to deter inebriated revelers from getting behind ... laws are being passed regarding drinking and driving," said study ...
(Date:12/15/2014)... December 15, 2014 Cancer researchers have ... underlying genetic causes of deadly malignant pleural mesothelioma. Surviving ... on their website. Click here to read it ... of Hawaii Cancer Center, and New York’s Langone Medical ... pleural mesothelioma patients in an effort to pinpoint ...
(Date:12/15/2014)... SIMpalm, a leading mobile app development ... for its client, which allows users to keep track ... in finding the right wine. At the center ... sensory, chemistry and wine information. All this information is ... Those wines that are close counterparts to one another ...
Breaking Medicine News(10 mins):Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2
... patients who present with advanced colorectal cancer that has spread to ... primary tumor in the colon. Researchers from Memorial Sloan-Kettering Cancer Center ... Oncology Annual Meeting. , ... population with metastatic disease that cannot be cured by surgery, undergoing ...
... May 30 Wyeth Pharmaceuticals, a division of Wyeth ... The American Society of Clinical Oncology (ASCO) Cancer Foundation ... provide patients with important health information and conduct physician ... the 45th Annual Meeting of the American Society of ...
... FRIDAY, May 29 (HealthDay News) -- Animals -- carnivores ... not necessarily develop bigger brains, say two biologists whose ... many evolutionists. , In a report published online ... Academy of Sciences Early Edition, John Finarelli of ...
... failure represents the most common reason for hospitalisation in ... the first 24 hours after admission in around 50% ... associated with a more than 50% mortality and rehospitalisation ... from the Cardiology Department of the University of Brescia, ...
... have been recently described in Heart Failure (HF) syndrome ... of acute decompensation. Biomarkers are used to diagnose disease ... individuals. , Speaking at a press conference at Heart ... for the European Society of Cardiology, presented these new ...
... of heart failure can be remotely assessed, now provide ... according to Professor John Cleland from the University of ... the management of heart failure is complex but most ... condition.2 "Unfortunately," he added, "the resources required to offer ...
Cached Medicine News:Health News:Surgery not necessary for most late-stage colorectal cancers 2Health News:Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care 2Health News:Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care 3Health News:Biologists Question Animal Brain Size Theory 2Health News:Better treatment selection and improved therapies -- key to improving prognosis in acute HF 2Health News:Novel biomarkers in heart failure 2Health News:Individualized treatment for heart failure is rarely available outside hospital 2
... are the only contact lenses designed to ... with aging eyes: presbyopia and eye dryness. ... superior lens design, Balanced Progressive Technology, with ... patented PC Technology. The result? Lenses that ...
... A miotic pupil is a commonly encountered complication ... remain unresponsive to routine topical agents, many surgeons ... gently stretch and retain the iris for maximum ... micro retractors are only 10mm long and can ...
... This instrument features a smooth, flat ... the irrigator. The uniquely designed tip ... the nucleus without endangering the posterior capsule. ... irrigation, and dual oval sideports help avoid ...
... 19 gauge universal irrigating chopper is designed for ... It features a bullet-shaped head for easy insertion ... tip for dividing and chopping the nucleus. ... fragments from underneath the iris which can be ...
Medicine Products: